Asset profile
Mesenchymal Precursor Cells (MPCs)
Cell therapy
Evidence outlook · lead readout
NCT00721045 · Heart Failure
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT00721045: The study randomized 60 participants to three MPC dose groups or sham procedures, with participants masked to assignment. However, the registry has no posted results for its primary safety and feasibility endpoint, so whether that endpoint was met cannot be determined.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.